medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2008, Number 5

<< Back Next >>

Salud Mental 2008; 31 (5)

Tabaquismo y depresión

Moreno CA, Medina-Mora IME

Language: Spanish
References: 67
Page: 409-415
PDF size: 108.44 Kb.


ABSTRACT

The objective of the present work is to review updated information about smoking and depression, based on a revision of Pub Med Data Base to find articles with the words «treatment», «smoking» and «depression» in the title, the summary, or the key words. The date of the most recent article reviewed was April of the 2008. An analysis of these articles was performed aiming to select the pertinent ones for the subject to treat in this summary. Additional articles were selected from references found in articles identified in the original revision. In addition, we offer a proposition about new research directions for depression and smoking, specially treatments for those patients who have simultaneously these disorders, since it’s important to design and evaluate new treatments against tobacco smoking habits. Treatments must have an integral approach, contemplating the psychological as well as the pharmacological intervention in order to achieve for a complete treatment.
Smoking and depression constitute two important worldwide and national public health problems. Tobacco addiction is worldwide one of the main causes of deterioration of the quality of life and increased morbi-mortality. It causes 5000000 deaths per year (one out of ten deaths of adults).The World Health Organization (WHO) estimated that according to present tendencies, in the year 2020, smoking habits will be responsible for ten million deaths, of which, seven out of ten will take place in developing countries. For the year 2030 tobacco smoking will be the main cause of death around the world.
In Mexico, according to the latest National Survey of Addictions, there were 14 million smokers, 9.6 million were former somkers and around 60000 people die every year due to illnesses directly related to smoking habits.
In adittion, in the year 2002 the WHO informed that depression was the prevailing disorders in general population with 154012 cases, affecting primarily women (62%) (95023 cases). This disorder is already the main cause of disability in the world, with 121 million people living with the disease. The estimation for the year 2020 is that it will be the second cause of labor loss in developed countries. In Mexico, depression is one of the main causes of mortality and burden of disease nation wide. A study focused on early depression in Mexican population, reported that 2.0% has suffered depression at some point during childhood or adolescence, and will present an average of seven depression episodes throughout their life.
During the last years, studies have shown a strong relation between smoking and depression. Therefore, people with history of depression have a tendency to develop tobacco addiction. Also, this kind of patients reveal an important reduction in the severity of the depressive symptoms when consuming nicotine. In spite of the evidence of the high comorbidity between these two diseases, their treatment is generally provided from an independent perspective, making it urgent to recognize the importance of their integrate attention.
In a study performed in order to determine the probability of occurrence of substance dependency disorder when affection disorders coexist, it was reported that dependency disorders occur before the abuse or dependency of substances in 47% of men and in 26% of women. In relation specifically to tobacco smoking habits, it has been reported that smokers who consume more than one pack per day have three times more probability of presenting symptoms of depression compared to nonsmokers.
It has been shown that patients with depressive symptomatolgy smoke as a way of self medication against this disabiling disease. Until now there is not enough information to predict if former smokers with depression can attain long term tobacco abstinence, as well as which would be are the effects produced by abstinence over depressive symptomatology. Because smokers with history of depression have a great probability of experiencing symptoms of the disease during abstinence, more research regarding treatment with antidepressants after abstincence period has been proved necessary.
Reviews are discussed in terms of their theoretical and clinical implications for smoking cessation research. Treatment of patients with both disorders must contemplate psychological and pharmacological attention. The appropriate medical attention of comorbid diseases will surely increase the rehabilitation´s rate of success.


REFERENCES

  1. Organización Mundial de la Salud. Disponible en: http://www.paho.org/english/ad/sde/ra/tobdefault.htm; 2007.

  2. Pan American Health Organization. Disponible en: http://www.paho.org/english/ad/sde/ra/tobdefault.htm; 2008.

  3. Organización Mundial de la Salud. http://www.who.int/healthinfo/statics/gbdwhoregionprevalence2002.xls; 2008.

  4. Encuesta Nacional de Adicciones (ENA) Secretaría de Salud y Consejo Nacional Contra las Adicciones. Disponible en: www.salud.gob.mx; 2002.

  5. SSA. Programa Nacional de Salud 2001 – 2006. Disponible en: http://www.salud.gob.mx/unidades/cdi/nom/compi/pns20012006.pdf; 2001.

  6. Kuri P, González J, Hoy M, Cortés M. Epidemiología del tabaquismo en México. Salud Pública Mex 2006;48:S91-S98.

  7. Villatoro J, Hernández I, Hernández H,Fleiz C, Blanco J et al. Encuesta de Consumo de Drogas de Estudiantes III 1991-2003 SEP- INPRFM. México: Disco compacto; ISB–968-7652-42–8; 2004.

  8. González-Pier E et al. Priority setting for health interventions in Mexico’s System of Social Protection in Health. Lancet 2006;368:1608-1618.

  9. Meneses F. Cultivo y producción de tabaco en México. En: Valdés R, Lazcano E, Hernández M (ed.). Primer informe sobre el combate al tabaquismo. México ante el convenio marco para el control del tabaco; 2005; p.289-296. Disponible en : http://www.insp.mx/tabaco/informe/parteXI.pdf.

  10. Sesma S, Pérez R, Puentes E, Valdés R. 2005 El precio como determinante del consumo de tabaco en México, 1994–2002. En: Valdés R, Lazcano E, Hernández M (ed.). Primer informe sobre el combate al tabaquismo. México ante el convenio marco para el control del tabaco; 2005. Disponible en: http://www.insp.mx/tabaco/informe/parteIV.pdf.

  11. Valdés R, Hernández M. La política fiscal aplicada al tabaco en México: 1980-2005. En: Valdés R, Lazcano E, Hernández M (ed.). Primer informe sobre el combate al tabaquismo. México ante el convenio marco para el control del tabaco; 2005; p. 109-113. Disponible en: http://www.insp.mx/tabaco/informe/parteIV.pdf.

  12. Reynales-Shigematsu LM, Rodríguez-Bolaños RA, Jiménez JA, Juarez-Marquez SA, Castro-Rios A et al. Costos de la atención médica atribuibles al consumo de tabaco en el Instituto Mexicano del seguro Social. Salud Pública Méx 2006;48(1):48-64.

  13. Barclay L, Kheyfets S. Tobacco use in Alzheimer´s disease. Prog Clin Biol Res 1989;317:189-194.

  14. Glassman A, Helzer JE, Covey LS. Smoking, smoking cessation and major depression. JAMA 1990;264:1546-1594.

  15. Salín- Pascual R, de la Fuente JR, Galicia-Polo L, Drucker-Colín R. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology 1995;121:476-479.

  16. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995;7:373.

  17. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. Am J Psychiatry 1997; 154:263-265.

  18. Mihailescu S, Drucker-Colín R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 2000;31:131-144.

  19. Fakhfakh R, Lagrue G. Depression, tobacco dependence and nicotine. Arch Inst Pasteur Tunis 2002;79:65-72.

  20. Hiroaki A, Suemaru K, Gomita Y. Neuronal nicotinic receptors and Psychiatric disorders: functional and behavioral effects of nicotine. Japn J Pharmacol 2002; 88:133-138.

  21. Breslau N, Novak SP, Kessler RC. Psychiatric disorders and stages of smoking. Biol Psychiatry 2004;55:69-76.

  22. Chang G, Sherritt L, Knight JR. Adolescent cigarette smoking and mental health symptoms. J Adolesc Health 2005;36(6):517-22.

  23. Crone MR, Reijneveld SA. The association of behavioural and emotional problems with tobacco use in adolescence. Addict Behav 2007;32(8):1692-8.

  24. Glasss RM. Blue mood, blackened lungs- depression and smoking. JAMA 1990;264:1583-1584.

  25. Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med 2008;121(4 supl 1): S20/s31.

  26. Greer S. Cancer and the mind. Br J Psychiatry 1983; 143:535-543.

  27. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res 2002;53:897-902.

  28. SERSAME. Servicios de Salud Mental. Disponible en: http://sersame.salud.gob.mx/depresion.htm#intro; 2002.

  29. Benjet C, Borges GG, Medina-Mora ME, Fleiz-Bautista C, Zambrano-Ruiz J. La depresión con inicio temprano: prevalencia, curso natural y latencia para buscar tratamiento. Salud Pública Mex 2004a;46(5):17-24.

  30. Medina-Mora ME, Borges G, Lara C, Benjet C, Blanco J et al. Prevalencia de trastornos mentales y uso de servicios: resultados de la Encuesa Nacional de Epidemiología Psiquiátrica. Salud Mental 2003;26(4): 1-16.

  31. Caraveo J, Colmenares E, Saldivar G. Estudio clínico-epidemiológico de los trastornos depresivos. Salud Mental 1999;22:7-17.

  32. Stage KB, Glassman AH, Covey LS. Depression after smoking cessation: case reports. J Clin Psychiatry 1996;57:467-469.

  33. Lai I, Hon Ch, Tsai S. Association study of nicotinic-receptor variants and major depressive disorder. J Affect Disord 2001;66(1):79-82.

  34. Hall SM, Muñoz R, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 1994;62(1):141-146.

  35. Munafò MR, Hitsman B, Rende R, Metcalfe C, Niaura R. Effects of progression to cigarette smoking on depressed mood in adolescents: evidence from the National Longitudinal Study of Adolescent Health. Addiction 2008;103(1):162-171.

  36. Catley D, Harris KJ, Okuyemi K, Mayo MS, Pankey E et al. The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. Nicotine Tob Res 2005;7(6): 859-870.

  37. Kassel JD, Yates M, Brown RA. Baseline reaction time predicts 12-month smoking cessation outcome in formerlydepressed smokers. Psychol Addict Behav 2007; 21(3):415-419.

  38. Medina-Mora ME, Borges G, Lara C, Benjet C, Blanco J et al. Prevalence, service use, and demographic correlatos of 12- month DSM-IV psychiatric disorders in México: results from the Mexican National Comorbidity Survey. Psychol Med 2005;35:1773-1783.

  39. Medina-Mora ME, Rojas-Guiot E, Borges-Guimaraes G, Vázquez-Perez L, Fleiz-Bautista C et al. Chapter 4-comorbidity: Depression and substance abuse. En: Aguilar-Gaxiola AS, Guillot TP (eds). Depression in Latinos. Springer Science Business Media LLC; 2008; p.73-90 (en prensa).

  40. Benjet C, Wagner FA, Borges GG, Medina-Mora ME. The relationship of tobacco smoking with depressive symptomatology in thr Third Mexican National Addictions Survey. TP 2004b;34(5):881-888.

  41. Pomerleau CS. Co-factors for smoking and evolutionary psychobiology. Addiction 1997;92(4):397-408.

  42. Salín-Pascual R, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport 1998;9:57-60.

  43. Hitsman B, Pingitore R, Spring B, Mahableshwarkar A, Mizes JS et al. Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol 1999;67:547-554.

  44. Pomerleau CS, Marks JL, Pomerleau OF. Who gets what symptom? Effect of psychiatric cofactor and nicotine dependence on patterns of smoking withdrawal symptomatology. Nicotine Tob Res 2000;2(3):275-280.

  45. Moreno-Coutiño A, Calderón-Ezquerro C, Drucker-Colín R. Long term changes in sleep and depressive symptoms of smokers in abstinente. Nicotine Tob Res 2007;9(3): 389-396.

  46. Covey LS, Glassman AH, Stetner F. Cigarette smoking and major depression. J Addict Dis 1998;17:35-46.

  47. Repko M, van den Brink W, Huyser J. Can depressed patients stop smoking? A review. Tijdschr Psychiatr 2007;49(10):753-62.

  48. Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Develpoments in pharmacotherapy for tobacco dependence past, present and future. Drug Alcohol Rev 2006; 25(1):59-71.

  49. Saxon AJ, Baer JS, Davis TM, Sloan KL, Malte CA et al. Smoking cessation treatment among dually diagnosed individuals: Preliminary evaluation of different pharcotherapies. Nicotine Tob Res 2003;5(4):589-596.

  50. Haug NA, Hall SM, Prochaska JJ, Rosen AB, Tsoh JY, et al. Acceptance of nicotine dependence treatment among currently depressed smokers. Nicotine Tob Res 2005; 7(2):217-24.

  51. Hughes JR. Depression during tobacco abstinence. Nicotine Tob Res 2007;9(4):443-6.

  52. Okuyemi KS, Ahluwalia JS, Harris KJ. Pharmacoherapy os Smoking Cessation. Arch Fam Med 2000;9:270-281.

  53. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;23(17):1195-202.

  54. Glover ED, Glover PN. Pharmacologic treatments for the nicotine dependent smoker. Am J Health Behav 2001; 25(3):179-82.

  55. Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI et al. Impact of prior nicotine replacement therapy on smoking cessation efficacy. Am J Health Behav 2002; 26(3):213-20.

  56. Fiore MC, Thompson SA, Lawrence DL, Welsch S, Andrews K et al. Helping Wisconsin women quit smoking: a successful collaboration. WMJ 2000;99(2):68-72.

  57. Cornuz J, Pinget C, Gilbert A, Paccaud F. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol 2003; 59(3):201-6.

  58. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006;15(4):280-5.

  59. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;4(9):685-691.

  60. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;23(1):CD000146.

  61. Thase ME, Greenhouse JB, Frank E, Reynolds CF 3rd, Pilkonis PA et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54(11):1009-15.

  62. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66(8):974-81.

  63. Wilkes S. Bupropion. Drugs Today (Barc) 2006; 42(10):671-81.

  64. Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 2007;9(7):721-30.

  65. Lerman C, Niaura R, Collins BN, Wileyto P, Audrain-McGovern J et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 2004;18(4):362-6.

  66. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J et al. A randomized trial of bupropion and&or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction 2007;102(8):1292-1302.

  67. Haro R, Drucker-Colín R. A two year study on the effects of nicotine and its withdrawal on mood and sleep. Pharmacopsychiatry 2004;37:1-7.




2020     |     www.medigraphic.com